Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Onconic Therapeutics Inc.
Onconic Therapeutics Inc.
Boehringer Ingelheim
Mayo Clinic
M.D. Anderson Cancer Center
Astellas Pharma Inc
University of Pennsylvania
Boehringer Ingelheim
Duke University
British Columbia Cancer Agency
Washington University School of Medicine
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Pennsylvania
Thomas Jefferson University
Fox Chase Cancer Center
Fudan University
Nelum Corp
Mateon Therapeutics
The First Affiliated Hospital with Nanjing Medical University
Rutgers, The State University of New Jersey
Sixth Affiliated Hospital, Sun Yat-sen University
University of Malaya
Ruijin Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
University Health Network, Toronto
University of Washington
Ruijin Hospital
First People's Hospital of Hangzhou
Ruijin Hospital
The Third Xiangya Hospital of Central South University
Tongji Hospital
Abramson Cancer Center at Penn Medicine
Campus Bio-Medico University
Wakayama Medical University
Yonsei University
Peking University Third Hospital
Wakayama Medical University
National Taiwan University Hospital
University of Utah
University of Virginia
Heidelberg University